Effect of Genetic Variation in the Transporter OCT2, MATE1 and MATE2-K on the PKPD of Metformin
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics
of a number of membrane transporters. The investigators will study individuals with
particular genotypes of the human organic cation transporter, (hOCT2), and the multidrug and
toxin extrusion transporters, MATE1, MATE2-K to test the hypothesis that genetic variation in
hOCT2, hMATEE1 and hMATE2-K are associated with variation in the pharmacokinetics and/or
pharmacodynamics of the antidiabetic agent, metformin.